Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Latest Insulin analog Stories

2014-04-03 12:30:42

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global and China Insulin Industry Report, 2013-2017 As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing...

2014-03-24 23:24:35

MarketOptimizer.org offers “PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store. Dallas, Texas (PRWEB) March 24, 2014 This report focuses on type 2 diabetes pharmaceuticals in seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) and three emerging markets (China, India and Brazil). These 10 markets will be referred to as the global market. The global type 2 diabetes pharmaceutical markets in the 2012...

2014-03-25 00:23:22

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/kz2b9w/investigation) has announced the addition of the "Investigation Report on China Insulin Glargine Market, 2009-2018" [http://www.researchandmarkets.com/research/kz2b9w/investigation ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) With the improvement of people's living standard and changing of...

2014-03-10 23:04:30

ChinaMarketResearchReports.com adds Latest Reports on China Insulin Aspart & Lispro Market to its store. Dallas, TX (PRWEB) March 10, 2014 According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with more than 380 million patients worldwide. On December 26, 2001 Novo Nordisk announced that the first insulin analogue insulin aspart (marketed by Novo Nordisk with the trade name "Novorapid") to treat...

2014-02-28 23:01:12

ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Insulin Glargine Market, 2009-2018” to its store. Dallas, TX (PRWEB) March 01, 2014 Description With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has...

2014-01-31 12:25:16

INDIANAPOLIS, Jan. 31, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has provided the following statement regarding a lawsuit filed by Sanofi in the United States District Court for the District of Delaware alleging patent infringement with respect to LY2963016, a new insulin glargine product for which Lilly is currently seeking approval from the U.S. Food and Drug Administration (FDA). "Lilly respects the intellectual property of others and does not believe the...

2013-12-02 20:22:24

COPENHAGEN, Denmark, December 2, 2013 /PRNewswire/ -- Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg(R) compared to biphasic...

2013-10-18 12:24:20

MISSISSAUGA, ON, Oct. 18, 2013 /CNW/ - Novo Nordisk today announced that Health Canada has approved Levemir((R)) FlexTouch((R)), a disposable prefilled insulin pen containing Levemir((R)) (insulin detemir). Levemir((R)) FlexTouch((R)) has been designed to improve ease of use for insulin administration and to help decrease barriers to good treatment adherence for Canadians living with type 1 and type 2 diabetes mellitus (diabetes). The approval was also announced at the 2013...

2013-09-18 23:22:38

The global market for insulin drug and delivery devices was valued at $24 billion in 2012 and is expected to reach $25.7 billion by 2013. BCC Research projects the market to reach nearly $40.2 billion by 2018 and register a compound annual growth rate (CAGR) of 9.3%. Wellesley, MA (PRWEB) September 18, 2013 According to a new technical market research report, Global Markets for Emerging Insulin Drug and Delivery Technologies from BCC Research (http://www.bccresearch.com), the global...

2013-06-24 12:25:44

CHICAGO, June 24, 2013 /PRNewswire/ -- Patients with type 2 diabetes, who are inadequately controlled on basal insulin plus oral anti-diabetic medications (OADs), obtained comparable reduction in A1c, whether they intensified with bolus insulin treatment step by step, or followed a full basal-bolus treatment with every meal from the start. Novo Nordisk presented data from the Full STEP(TM) study today at the 73(rd) Scientific Sessions of the American Diabetes Association (ADA)....